High expression of the Met receptor in prostate cancer metastasis to bone. - Wikidata - wikimedia - TriplyDB

High expression of the Met receptor in prostate cancer metastasis to bone.

High expression of the Met receptor in prostate cancer metastasis to bone.

http://www.wikidata.org/entity/Q34163761

about

Molecular pathology of prostate cancer Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics Growth factor and signaling pathways and their relevance to prostate cancer therapeutics Targeting bone physiology for the treatment of metastatic prostate cancer Met in urological cancers Cellular Plasticity in Prostate Cancer Bone Metastasis Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE)Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.Plexin-B1 mutations in prostate cancer.Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.Efficacy of c-Met inhibitor for advanced prostate cancer.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.Activation of the MEK-S6 pathway in high-grade ovarian cancers.Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.The biology of castration-resistant prostate cancer Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.MET and VEGF: synergistic targets in castration-resistant prostate cancer Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein Bone-targeted agents in the treatment of lung cancer.Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.Emerging targeted therapies for castration-resistant prostate cancer.Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.Ligand-independent activation of MET through IGF-1/IGF-1R signaling.Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation.Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.

P2860

Q24672410-C8540535-A7B5-4C89-92AE-02E492370038 Q26741450-142DFF26-4031-4FA2-AEFA-C7113BDC4D96 Q26773613-A73B89B1-70D2-484D-9AA8-5B80931D832F Q26827975-820DDFF2-93E9-4B50-9A8A-CEB13742BD92 Q26863249-B8091AC7-12C4-4D13-A35F-DF2E8DBF3927 Q26864988-8F98AD4C-04A3-4D34-BEA5-4376E17BBE3C Q28085013-B8F8507E-3CBE-4142-BE1D-A407EC0DC28E Q28652074-20448418-9817-4284-9182-217A6EDA7346 Q30409623-F823E2CA-FE6E-4488-9FFC-F7AF4618EAAB Q30446159-5C0A5752-38B7-497F-AF15-F48F5D54CCCE Q30480866-464E9B7C-E737-4855-B696-37C3DB7F1514 Q30572057-2A97E201-8C7A-4D88-8BBE-20E08FA5D72D Q31062741-17C3FE3F-21C7-4A5C-AFDC-7B60C076BC21 Q33645250-4C6CBB8A-3F71-4250-A7EA-135A2ED40639 Q33718726-9D737963-99F0-4027-A494-711ECB3B0ABE Q33769437-DED8CBE7-F08B-4A70-87A0-A98679B67387 Q33946929-467613A1-BE6A-437B-B352-E957C356ABE6 Q34309227-7B4F9E20-0FEF-4293-8C2B-77008DB5DF31 Q34339010-925F883B-DF68-410F-912E-17651ACD9755 Q34854941-7F13E752-ABA1-487D-B613-A4879355D88C Q35039889-4AF8A335-F0C4-4A37-A383-14B2B5FD01B2 Q35102980-7DAAD06E-E9FC-42A4-9EA8-2C63A55E7B02 Q35224818-266F4BBE-D0CC-4731-8705-A79D8B541FEE Q35575488-1FEA8305-30EC-4956-BFD5-DDE21D39F9AE Q35747784-8EF55F24-B774-4587-880F-6FA4104920FF Q35780792-25282704-7869-4BE5-880F-E64471C97802 Q35985270-ABCFCC25-5142-4023-826A-979CA2049E80 Q35999255-EF078595-9308-4ED9-BF40-C0F5FC4CC79C Q36051783-B1B71DDF-3141-4B6B-B54C-94DBA3BF0952 Q36162776-A42B57F8-8DF1-4B6D-B67C-BED0C822DAF4 Q36172754-43F37139-7513-4E50-BE99-007DDDB21758 Q36290408-622F0937-28E5-4A4D-8864-C16FE3EB41B0 Q36436763-457C3909-1C40-4D74-857F-C2A540C8D4E8 Q36515134-086E9BB7-7CD3-408A-B2EA-BF225FAE132A Q36840731-89FE372A-0E54-4F5E-B5EA-B3C2F03777C4 Q36931715-E281A090-4EAA-4874-8EBF-C2528B010E10 Q36934749-C8D9F2A3-C8E4-4A83-AADA-5CDB4E910C5A Q37018397-043CA861-3551-4F0B-A46A-5CE26ABE467E Q37341925-93880C35-B7C0-4DCE-9B6E-41A8726F4D4C Q37445062-A4873358-E67E-43BC-B16B-428283EF8FAC

P2860

High expression of the Met receptor in prostate cancer metastasis to bone.

http://www.wikidata.org/entity/Q34163761

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

High expression of the Met receptor in prostate cancer metastasis to bone.

@ast

High expression of the Met receptor in prostate cancer metastasis to bone.

@en

High expression of the Met receptor in prostate cancer metastasis to bone.

@nl

type

label

High expression of the Met receptor in prostate cancer metastasis to bone.

@ast

High expression of the Met receptor in prostate cancer metastasis to bone.

@en

High expression of the Met receptor in prostate cancer metastasis to bone.

@nl

prefLabel

High expression of the Met receptor in prostate cancer metastasis to bone.

@ast

High expression of the Met receptor in prostate cancer metastasis to bone.

@en

High expression of the Met receptor in prostate cancer metastasis to bone.

@nl

P1433

Q34163761-41A337DB-FF9F-4B5A-BAD0-E61AEB5D831F

P1476

Q34163761-EBB78B3E-06F7-4623-91DE-A10D829AE061

P2093

Q34163761-1120310C-35A5-4161-B116-B0FD613CF527

Q34163761-17470842-647D-4F58-A52A-6589FCFB58B7

Q34163761-469F9C5A-AEF0-4A73-9159-8D18D257FFDA

Q34163761-5DE1E33A-31E5-4A00-A528-9141053C59D3

Q34163761-710DA6B0-FD9A-43E1-BDCD-175ABC4352C0

Q34163761-96C9CF39-9FD0-47DA-A6ED-022F19F677F1

Q34163761-C0BA896C-F04B-4E17-AF44-F61AA2A72D91

Q34163761-CA24070C-20B5-4C14-9DDE-08A07E7E711C

Q34163761-F94DE4E0-C141-483F-ACC4-470C9D3A0F94

P304

Q34163761-E64CC555-FF67-4F8A-BE47-78E981110C70

P31

Q34163761-3B677144-9B3A-4F2F-8426-FF19E0FDEB6A

P356

Q34163761-852665ED-6F70-47CD-921E-63B5A5E8E8D8

P407

Q34163761-A1665ABE-B943-446C-94A8-2C95E551EC89

P433

Q34163761-B6967D68-82CF-4465-8D58-D0EAC4F41C9A

P478

Q34163761-6125F3E3-D0BB-4560-BD63-9EC7CE182669

P577

Q34163761-373FDA05-8B70-4D7D-9994-934B82E4E7D2

P698

Q34163761-229077D9-2760-4913-9270-968D040318C4

P356

S0090-4295(02)01954-4

P1433

P1476

High expression of the Met receptor in prostate cancer metastasis to bone.

@en

P2093

Beatrice S Knudsen

http://www.w3.org/2001/XMLSchema#string

David M Nanus

http://www.w3.org/2001/XMLSchema#string

Douglas S Scherr

http://www.w3.org/2001/XMLSchema#string

E Darracott Vaughan

http://www.w3.org/2001/XMLSchema#string

George F Vande Woude

http://www.w3.org/2001/XMLSchema#string

Glenn A Gmyrek

http://www.w3.org/2001/XMLSchema#string

Jennifer Inra

http://www.w3.org/2001/XMLSchema#string

Michael W Kattan

http://www.w3.org/2001/XMLSchema#string

William L Gerald

http://www.w3.org/2001/XMLSchema#string

P304

1113-1117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0090-4295(02)01954-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12475693

http://www.w3.org/2001/XMLSchema#string